QuidelOrtho Corp. Stock
€37.20
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 0.540% | 1.087% | -14.345% | -54.423% | -45.149% | -62.598% | - |
Boston Scientific | 0.000% | 7.874% | 9.320% | 47.884% | 33.165% | 95.938% | 105.706% |
Illumina Inc. | 2.160% | 3.684% | -7.406% | -40.261% | -11.066% | -67.161% | -59.025% |
Waters Corp. | 0.590% | 5.210% | -8.553% | 7.704% | -3.709% | 15.397% | 51.727% |
Comments
News
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test. This clearance allows